(Reuters) -Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder that affects bone tissue has met the main goal of a late-stage trial.
The company said its drug, garetosmab, was highly efficacious in reducing abnormal bone growth in patients with fibrodysplasia ossificans progressiva.
The condition causes muscle, tendon and ligament tissue to gradually turn into bone, leading to a “second skeleton” that restricts movement and mobility.
The company said it plans to submit a marketing application for the drug in the U.S. by the end of 2025.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Brought to you by www.srnnews.com
